ACADIA PHARMACEUTICALS INC. (ACAD) Operating Margin
- Operating margin · 12 months: Value 7.59%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 7.59% | Operating income / revenue. Period ending 2026-06-30. $86.37M ÷ $1.14B × 100 ≈ 7.59% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 86.37M USD | Operating Income (Loss) |
| Revenue | 1.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 100.98M USD | Cost of Goods and Services Sold |
| Research and development | 331.01M USD | Research and Development Expense |
| Selling, general and administration | 620.29M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $86.37M | $1.14B | $100.98M | $331.01M | $620.29M | 7.59% |
| 2026-03-31 | $80.91M | $1.10B | $93.40M | $327.40M | $593.54M | 7.39% |
| 2025-12-31 | $104.81M | $1.07B | $89.00M | $328.80M | $548.89M | 9.78% |
| 2025-09-30 | $240.92M | $1.05B | $84.58M | $344.78M | $523.36M | 23.01% |
| 2025-06-30 | $236.81M | $1.02B | $81.79M | $323.55M | $523.25M | 23.24% |
| 2025-03-31 | $234.87M | $996.28M | $79.28M | $321.83M | $506.81M | 23.58% |
| 2024-12-31 | $230.79M | $957.80M | $81.84M | $303.25M | $488.43M | 24.10% |
| 2024-09-30 | $112.23M | $929.24M | $77.93M | $269.26M | $469.81M | 12.08% |
| 2024-06-30 | $22.82M | $890.53M | $73.69M | $359.62M | $434.41M | 2.56% |
| 2024-03-31 | $-4.58M | $813.81M | $62.92M | $342.15M | $413.31M | -0.56% |
| 2023-12-31 | $-73.38M | $726.44M | $41.64M | $351.62M | $406.56M | -10.10% |
| 2023-09-30 | $-154.39M | $631.89M | $26.16M | $360.62M | $399.50M | -24.43% |
| 2023-06-30 | $-127.48M | $550.90M | $13.68M | $284.99M | $379.71M | -23.14% |
| 2023-03-31 | $-164.16M | $520.23M | $8.88M | $301.86M | $373.65M | -31.56% |
| 2022-12-31 | $-223.60M | $517.24M | $10.17M | $361.57M | $369.09M | -43.23% |
| 2022-09-30 | $-222.19M | $511.50M | $10.20M | $352.78M | $370.60M | -43.44% |
| 2022-06-30 | $-206.63M | $512.40M | $11.75M | $330.01M | $374.16M | -40.32% |
| 2022-03-31 | $-216.68M | $493.06M | $11.61M | $311.30M | $381.05M | -43.95% |
| 2021-12-31 | $-170.44M | $484.14M | $10.84M | $239.41M | $396.03M | -35.20% |
| 2021-09-30 | $-192.94M | $474.39M | $10.91M | $234.59M | $410.87M | -40.67% |
| 2021-06-30 | $-263.54M | $463.36M | $9.22M | $296.11M | $410.79M | -56.88% |
| 2021-03-31 | $-263.84M | $458.24M | $9.60M | $303.47M | $398.35M | -57.58% |
| 2020-12-31 | $-286.59M | $441.75M | $10.21M | $319.13M | $388.66M | -64.87% |
| 2020-12-30 | (m) | $441.75M | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-275.82M | $419.07M | $10.72M | $314.53M | $359.78M | -65.82% |
| 2020-06-30 | $-235.34M | $393.08M | $11.13M | $257.07M | $350.88M | -59.87% |
| 2020-03-31 | $-248.43M | $366.19M | $11.19M | $260.10M | $334.52M | -67.84% |
| 2019-12-31 | $-246.54M | $339.08M | $11.34M | $240.38M | $325.64M | -72.71% |
| 2019-09-30 | $-257.42M | $300.32M | (m) | $231.05M | $308.04M | -85.72% |
| 2019-06-30 | $-273.27M | $264.04M | (m) | $221.54M | $296.43M | -103.50% |
| 2019-03-31 | $-280.26M | $237.90M | (m) | $200.81M | $297.92M | -117.81% |
| 2018-12-31 | $-247.44M | $223.81M | (m) | $187.16M | $265.76M | -110.56% |
| 2018-09-30 | $-250.18M | $207.80M | (m) | $182.16M | $258.18M | -120.39% |
| 2018-06-30 | $-254.55M | $185.07M | (m) | $165.47M | $258.68M | -137.54% |
| 2018-03-31 | $-258.51M | $158.48M | (m) | $153.06M | $250.33M | -163.11% |
| 2017-12-31 | $-292.41M | $124.90M | (m) | $149.19M | $255.06M | -234.11% |
| 2017-09-30 | $-301.78M | $93.30M | (m) | $136.23M | $247.19M | -323.45% |
| 2017-06-30 | $-307.87M | $62.99M | (m) | $125.62M | $235.47M | -488.75% |
| 2017-03-31 | $-311.36M | $32.61M | (m) | $111.92M | $224.71M | -954.71% |
| 2016-12-31 | $-272.81M | $17.33M | (m) | $99.28M | $186.46M | -1574.14% |
| 2016-09-30 | $-240.15M | $5.39M | (m) | $89.53M | (m) | -4458.76% |
| 2016-06-30 | $-206.75M | $157.00K | (m) | $82.45M | (m) | -131686.62% |
| 2016-03-31 | $-174.32M | $61.00K | (m) | $80.35M | (m) | -285773.77% |
| 2015-12-31 | $-164.61M | $61.00K | (m) | $73.87M | (m) | -269855.74% |
| 2015-09-30 | $-147.60M | $92.00K | (m) | $71.58M | (m) | -160435.87% |
| 2015-06-30 | $-133.60M | $67.00K | (m) | $69.81M | (m) | -199400.00% |
| 2015-03-31 | $-115.82M | $94.00K | (m) | $65.23M | (m) | -123217.02% |
| 2014-12-31 | $-93.23M | $120.00K | (m) | $60.60M | (m) | -77691.67% |
| 2014-09-30 | $-76.84M | $109.00K | (m) | $50.34M | (m) | -70495.41% |
| 2014-06-30 | $-62.66M | $335.00K | (m) | $40.65M | (m) | -18703.58% |
| 2014-03-31 | $-50.09M | $758.00K | (m) | $33.96M | (m) | -6608.31% |
| 2013-12-31 | $-38.30M | $1.15M | (m) | $26.72M | (m) | -3344.72% |
| 2013-09-30 | $-32.95M | $1.49M | (m) | $23.70M | (m) | -2214.52% |
| 2013-06-30 | $-24.55M | $4.73M | (m) | $20.84M | (m) | -519.40% |
| 2013-03-31 | $-20.82M | $4.87M | (m) | $18.20M | (m) | -427.14% |
| 2012-12-31 | $-20.89M | $4.91M | (m) | $18.79M | (m) | -425.64% |
| 2012-09-30 | $-19.38M | $5.12M | (m) | $18.32M | (m) | -378.91% |
| 2012-06-30 | $-22.07M | $2.22M | (m) | $18.07M | (m) | -993.56% |
| 2012-03-31 | $-23.22M | $2.08M | (m) | $17.92M | (m) | -1115.37% |
| 2011-12-31 | $-22.85M | $2.07M | (m) | $17.31M | (m) | -1105.56% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $15.09M | $42.13M | (m) | $20.58M | (m) | 35.82% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-45.47M | $6.40M | (m) | $41.59M | (m) | -710.55% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |